Professor and Chairman of Neurology
Neurology
Dr. Michael K. Racke, MD
|
|
Give Review
Michael Racke is an expert in the field of Neurology. He went to Rutgers New Jersey Medical School. Rutgers New Jersey Medical School is ranked 76/0 in Research/PrimaryCare. He received awards:"CMS Meaningful Use Stage 1 Certification" and "Harry Weaver Neuroscience Scholar". Michael Racke is also published. He has 100 publications published. The lastest publication: "IL-4-induced immune deviation as antigen-specific therapy for inflammatory autoimmune disease.' Dr. Michael K. Racke accepts Medicare.
Publications
- Will Biomarkers Determine What Is Next in Multiple Sclerosis?: Biomarkers in Multiple Sclerosis.
- Responsibilities of Health Care Professionals in Counseling and Educating Patients With Incurable Neurological Diseases Regarding "Stem Cell Tourism": Caveat Emptor.
- Concise Review: Modeling Multiple Sclerosis With Stem Cell Biological Platforms: Toward Functional Validation of Cellular and Molecular Phenotypes in Inflammation-Ind...
- Analysis of TGF-β1 and TGF-β3 as regulators of encephalitogenic Th17 cells: Implications for Multiple sclerosis.
- Is No Evidence of Disease Activity a Realistic Goal for Patients With Multiple Sclerosis?
- High-Dose Immunosuppressive Therapy and Autologous Hematopoietic Cell Transplantation for Relapsing-Remitting Multiple Sclerosis (HALT-MS): A 3-Year Interim Report.
- Impact of suppressing RORγt in ameliorating central nervous system autoimmunity.
- First-line natalizumab in Multiple sclerosis: rationale, patient selection, benefits and risks.
- Multiple sclerosis: Five new things.
- Interferon beta use and disability prevention in relapsing-remitting Multiple sclerosis.
- Multiple sclerosis: The potassium channel KIR4.1-a potential autoantigen in MS.
- miR-29ab1 Deficiency Identifies a Negative FeedBack Loop Controlling Th1 Bias That Is Dysregulated in Multiple Sclerosis.
- Dimethyl fumarate inhibits dendritic cell maturation via nuclear factor kcyB (NF-kcyB) and Extracellular Signal-regulated kinase 1 and 2 (ERK1/2) and Mitogen Stress ac...
- miRNA profiling for biomarker Discovery in multiple sclerosis: From microarray to deep sequencing.
- Fumarates improve psoriasis and Multiple sclerosis by inducing type II dendritic cells.
- TGF-? signaling via smad4 drives IL-10 production in effector Th1 cells and reduces T cell trafficking in EAE.
- Comparison of a classical Th1 bacteria versus a Th17 bacteria as adjuvant in the induction of experimental autoimmune encephalomyelitis.
- Glatiramer acetate treatment of Multiple sclerosis: an immunological perspective.
- Rituximab therapy reduces organ-specific T cell responses and ameliorates experimental autoimmune encephalomyelitis.
- Understanding the effects of FTY720 on leukocyte trafficking.
- Translational research in neurology and neuroscience 2010: Multiple sclerosis.
- Hematopoietic stem cell transplantation for Multiple sclerosis: collaboration of the CIBMTR and EBMT to facilitate international clinical studies.
- Natalizumab and progressive multifocal leukoencephalopathy: what are the causal factors and can it be avoided?
- TGF-beta enhances effector Th1 cell activation but promotes self-regulation via IL-10.
- Silencing Nogo-A promotes functional recovery in demyelinating Disease.
- The mechanism of action of glatiramer acetate treatment in Multiple sclerosis.
- Regulation of Immune Responses and Autoimmune Encephalomyelitis by PPARs.
- T-bet is Essential for encephalitogenicity of both Th1 and Th17 cells.
- Progressive multifocal leukoencephalopathy and relapsing-remitting Multiple sclerosis: a comparative study.
- Transcriptional modulation of the immune response by peroxisome proliferator-activated receptor-{alpha} agonists in autoimmune Disease.
- Genetic polymorphism at codon 129 of the prion protein gene is not associated with Multiple sclerosis.
- PEG minocycline-liposomes ameliorate CNS autoimmune Disease.
- Decrease in the numbers of dendritic cells and CD4+ T cells in Cerebral perivascular spaces due to natalizumab.
- Impact of myelin-specific antigen presenting B cells on T cell activation in Multiple sclerosis.
- Monoclonal antibody therapies and neurologic Disorders.
- Reactivation of human herpesvirus-6 in natalizumab treated Multiple sclerosis patients.
- PPAR-gamma: Therapeutic Potential for Multiple Sclerosis.
- PPAR Alpha Regulation of the Immune Response and Autoimmune Encephalomyelitis.
- PPARs in Neuroinflammation.
- Humoral immune responses after rabies infection.
- High incidence of post-lumbar puncture Headaches in patients with multiple sclerosis treated with natalizumab: role of intrathecal leukocytes.
- T-bet regulates the fate of Th1 and Th17 lymphocytes in autoimmunity.
- Altered CD4+/CD8+ T-cell ratios in cerebrospinal fluid of natalizumab-treated patients with Multiple sclerosis.
- Therapeutic induction of regulatory, cytoToxic CD8+ T cells in multiple sclerosis.
- Epstein-Barr virus and Multiple sclerosis.
- Immune surveillance in Multiple sclerosis patients treated with natalizumab.
- Multiple sclerosis--the plaque and its pathogenesis.
- Nuclear receptors and autoimmune Disease: the potential of PPAR agonists to treat multiple sclerosis.
- Therapeutic potential of small interfering RNA for central nervous system Diseases.
- Therapeutic considerations for Disease progression in multiple sclerosis: evidence, experience, and future expectations.
- Agonists for the peroxisome proliferator-activated receptor-alpha and the retinoid X receptor inhibit Inflammatory responses of microglia.
- Glatiramer acetate therapy: the plot thickens.
- Recommended standard of cerebrospinal fluid analysis in the diagnosis of Multiple sclerosis: a consensus statement.
- Effect of rituximab on the peripheral blood and cerebrospinal fluid B cells in patients with primary progressive Multiple sclerosis.
- Silencing T-bet defines a critical role in the differentiation of autoreactive T lymphocytes.
- High prevalence of autoreactive, neuroantigen-specific CD8+ T cells in Multiple sclerosis revealed by novel flow cytometric assay.
- Peroxisome proliferator-activated receptor alpha agonists as therapy for autoimmune Disease.
- Mycophenolate mofetil in Multiple sclerosis.
- Fatigue in Multiple sclerosis: is the picture getting simpler or more complex?
- IL-1 receptor-associated kinase 1 regulates susceptibility to organ-specific autoimmunity.
- Expression of the tyrosine phosphatase SRC homology 2 domain-containing protein tyrosine phosphatase 1 determines T cell activation threshold and severity of experimen...
- Peroxisome proliferator-activated receptor-gamma agonist 15-deoxy-Delta(12,14)-prostaglandin J(2) ameliorates experimental autoimmune encephalomyelitis.
- Glatiramer acetate (Copaxone) therapy induces CD8(+) T cell responses in patients with Multiple sclerosis.
- Retinoic acid promotes the development of Th2-like human myelin basic protein-reactive T cells.
- Analysis of miRNA in Normal Appearing White Matter to Identify Altered CNS Pathways in Multiple Sclerosis.
- Design of oral agents for the management of Multiple sclerosis: benefit and risk assessment for dimethyl fumarate.
- Cerebral vascular endothelial cells are effective targets for in vitro lysis by encephalitogenic T lymphocytes.
- IL-4-induced immune deviation as antigen-specific therapy for inflammatory autoimmune Disease.
- To treat, or not to treat: the therapeutic dilemma of idiopathic monosymptomatic demyelinating Syndromes.
- Levetiracetam for phasic spasticity in Multiple sclerosis.
- Disease-modifying therapy in multiple sclerosis: strategies for optimizing management.
- Viral pathogens in Multiple sclerosis: an intriguing (hi)story.
- Factors that influence adherence with Disease-modifying therapy in MS.
- Cerebrospinal fluid B cells from Multiple sclerosis patients are subject to normal germinal center selection.
- Efficacy, safety, and cost-effectiveness of glatiramer acetate in the treatment of relapsing-remitting Multiple sclerosis.
- Toll-like receptors in Multiple sclerosis.
- Potential of a unique antibody gene signature to predict conversion to clinically definite Multiple sclerosis.
- Pharmacological prion protein silencing accelerates central nervous system autoimmune Disease via T cell receptor signalling.
- Th1 versus Th17: are T cell cytokines relevant in Multiple sclerosis?
- Novel therapeutic strategies targeting the pathogenic T-cells in Multiple sclerosis.
- The potential role of B cell-targeted therapies in Multiple sclerosis.
- miRNAs in Multiple sclerosis: regulating the regulators.
- Memory B cells from a subset of treatment-naïve relapsing-remitting Multiple sclerosis patients elicit CD4(+) T-cell proliferation and IFN-γ production in response to ...
- A randomized, blinded, parallel-group, pilot trial of mycophenolate mofetil (CellCept) compared with interferon beta-1a (Avonex) in patients with relapsing-remitting m...
- A one-year prospective, randomized, placebo-controlled, quadruple-blinded, phase II safety pilot trial of combination therapy with interferon beta-1a and mycophenolate...
- Natalizumab: Increased Vigilance is Required in Treating Patients with Multiple Sclerosis.
- Challenges in developing new Multiple sclerosis therapies.
- Pharmacotherapy of Multiple sclerosis: the PROOF trial.
- Micro-RNA dysregulation in multiple sclerosis favours pro-Inflammatory T-cell-mediated autoimmunity.
- Because it is our journal.
- Clonal composition of neuroantigen-specific CD8+ and CD4+ T-cells in Multiple sclerosis.
- What happens when natalizumab therapy is stopped?
- Peroxisome proliferator-activated receptor-alpha and retinoid X receptor agonists inhibit Inflammatory responses of astrocytes.
- Peroxisome proliferator-activated receptor agonist regulation of glial activation: relevance to CNS inflammatory Disorders.
- Glatiramer acetate (GA) therapy induces a focused, oligoclonal CD8+ T-cell repertoire in Multiple sclerosis.
- Phenotypic characterization of autoreactive T cells in Multiple sclerosis.
- CD28-CD57+ T cells predominate in CD8 responses to glatiramer acetate.
- CD28:B7 interaction is necessary for the protective effect of T cell vaccination in EAE.
- Antigen specificity of clonally expanded and receptor edited cerebrospinal fluid B cells from patients with relapsing remitting MS.
Conditions Treated
- Alzheimer's Background: yellow;'>Background: yellow;'>Disease
- Anterior Horn Background: yellow;'>Background: yellow;'>Disease
- Ataxia
- Autonomic Disorders
- View All
Doctors Specialties
- Neurology
Accepted Insurances
Awards
- CMS Meaningful Use Stage 1 Certification
- Harry Weaver Neuroscience Scholar
Education
-
Emory University -
Rutgers New Jersey Medical School
Hospital
-
Ohio State University Wexner Medical Center
Drug Facts
| NPI NUMBER | 1821052721 | |
| NPPES Provider LastName | RACKE | |
| NPPES Provider FirstName | MICHAEL | |
| NPPES Provider ZIPCode | 432213502 | |
| NPPES Provider State | OH | |
| Specialty Description | Neurology | |
| Total Claim Count | 154.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1821052721 |
| Last Name Of The Provider | RACKE |
| First Name Of The Provider | MICHAEL |
| View All |
Similar Doctors
|
Dr. John T. Kissel, MD
 This Doctor is OpenDoctor Recommended.
|
|
Dr. Maria Kataki, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. David Hinkle, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Geoffrey L. Heyer, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Sandra K. Kostyk, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Addie K. Patterson, DO |
|
|
Dr. Mehr A. Siddiqui, MD
This Doctor is OpenDoctor Recommended.
|